Increasingly, the great new medical technologies aren’t coming from the pharmaceutical behemoths, but from scrappy little biotech upstarts. In few instances is this truer than in the field of cancer immunotherapy.
Immunotherapy is defined as a “treatment designed to produce immunity to disease or enhance the resistance of the immune system to an active disease process, as cancer.” Simply put, cancer immunotherapy activates the body’s powerful and complex immune system so that it can do its job better.
Immune system-based therapies are becoming a proven route to improving cancer treatment. There are multiple immunotherapy innovators, several of which have performed well in our Technology Profits Confidential portfolio due to their deep and diverse developmental pipelines.
Some immune-based therapies work, for example, by training the immune system to identify and attack cancer cells. Functionally, therefore, they are vaccines.
Others use antibodies to achieve similar results. Antibodies are an important part of our natural biological defenses. They are used by the immune system to identify infectious microbes and mutant cancer cells. Once these foreign objects are flagged by antibodies, other immune system components, such as white blood cells, move in for the kill.
ADC (antibody-drug conjugation) technology, for example, works by combining an immune system component — antibodies — with a toxic payload.
ADC technology uses engineered antibodies to target molecular markers that are overexpressed on cancer cells, yet absent or uncommon on healthy ones. The attached toxin is then released to kill the cell.
Another kind of ADC technology doesn’t link antibodies directly to cancer cells, but instead, attach an antigen to an antibody that is targeted to attach to antigen-presenting cells (APCs) — specifically, dendritic cells. Once attached to a dendritic cell, it presents an antigen that’s frequently present in a wide variety of cancer types, including sarcoma, myeloma, melanoma and cancer of the bladder, breast, ovaries and lungs.
Many antibody-based cancer immunotherapy companies imitate this natural defense mechanism by creating custom antibodies to home in on molecular targets present on cancer cells. Once an immune system cell, such as a T-cell, comes into contact with an attached antibody, it attacks the tagged cancer cell.
Then there’s technology that uses compounds that aren’t antibodies, but protein that stimulates the immune system by proliferating and mobilizing bone marrow stem cells and immune cells.
When choosing different companies that specialize in this kind of technology, many factors come into play. But when picking companies undergoing trials, it’s better to go with fully human antibody therapeutics over “humanized” mouse (or any other animal) antibody.
When it’s fully human, it should be better tolerated by human patients. Humans can have an immune reaction to nonhuman antibodies, paradoxically producing their own antibodies to the therapeutic antibody. This causes the patient’s immune system to destroy the therapeutic antibodies.
This can reduce the effectiveness of an antibody therapy and require more frequent dosing. And because antibody drugs are large proteins that must be administered through injection, the frequency of dosing is important to patients.
Takeaway: keep these kinds of immunotherapy approaches in mind when looking for biotech companies with high growth potential.
Ad lucrum per scientia (toward wealth through science),
Why responsibility and entrepreneurship could increase US GDP in a very substantial way...
In 8th grade Ray Blanco was in his basement learning how to build what's called a "Wilson Cloud Chamber," a supercooled device for detecting particles of ionizing radiation. Now, he is an expert in advanced robotics, avionics, genomics, and biotechnology. Blanco was raised in Miami,FL, after his family fled Cuba in the 1960s. He is co-editor of Technology Profits Confidential and contributes to Breakthrough Technology Alert and Tomorrow in Review.
America's most precious resource isn't oil, natural gas, gold or any other commodity. But it travels through an extensive pipeline that, if severed, could signal an unprecedented breach in U.S. security. What is this pipeline, and why is it so imperative that the U.S. take steps to protect it? Byron King explains...
There is no problem the U.S. government thinks it can't fix. Whether it's a foreign conflict between two sovereign nations, or it's own battered housing market. Today, Doug French examines a new study that shows, with alarming clarity, how government intervention hinders rather than helps, any hope of a speedy recovery. Read on...
With the gold price on the rise in 2014, more and more investors are starting to take notice of the yellow metal. But one sector of this market is starting to head higher that almost no one predicted. Greg Guenthner explains why, in order to get the biggest gains out of this sector, now is the time to act. Read on...
Due to ongoing strikes in South Africa - which have knocked 40% off of expected global output of the platinum group metals (PGMs) - the price of PGMs is skyrocketing. Byron King explains why, short-term this could be a great play for savvy investors, but why long-term, this is a much more serious issue than people realize...
The military crisis in Crimea currently favors Russia. It's established a strong foothold in the region, and most of the people their identify themselves as Russian. So why is the US - which has no national interest in Crimea - so intent on taking sides in the conflict? Byron King explains...